Update: Alumis Shares Fall After Phase 2 Trial of Envudeucitinib in Lupus Misses Goals in Overall Trial Population

02:06 PM EDT, 09/01/2026 (MT Newswires) -- (Updates with latest stock price movement in the headline and first paragraph.) Alumis (ALMS) shares were down nearly 59% in Tuesday trading after the company said a phase 2 study of its envudeucitinib experimental drug in moderate-to-severe systemic lupus erythematosus failed to meet its primary and secondary endpoints in the overall trial population. The company said a pre-specified subgroup of patients with high interferon gene signature showed "robust" responses that could support a path forward for regulatory engagement on a phase 3 study. Alumis said the IFNGS-high group was under-represented in the trial, which affected the overall results. The company said it plans to engage regulators to discuss phase 3 development of envudeucitinib in lupus erythematosus, while it remains on track to file a new drug application in Q4 for envudeucitinib in moderate-to-severe plaque psoriasis. Price: 9.00, Change: -12.81, Percent Change: -58.73